Document is current
Any future updates will be listed below
-
Authors
Regensburger, Martin https://orcid.org/0000-0002-2172-7386
Csoti, Ilona https://orcid.org/0000-0002-3867-6837
Jost, Wolfgang H. https://orcid.org/0000-0002-8574-3297
Kohl, Zacharias https://orcid.org/0000-0002-4147-8866
Lorenzl, Stefan https://orcid.org/0000-0002-1165-0821
Pedrosa, David J. https://orcid.org/0000-0002-5403-1959
Lingor, Paul https://orcid.org/0000-0001-9362-7096
-
Funding
Funding for this research was provided by:
Technische Universität München
- License Information
-
More Information
Article History
Received: 19 May 2025
Accepted: 14 July 2025
First Online: 28 July 2025
Declarations
:
: MR is funded by the German Federal Ministry of Education and Research (ACS_iIMMUNE, 01EO2105). He was consultant and / or speaker for Zambon GmbH, Ever Pharma GmbH, Abbvie GmbH and Bial GmbH, and he received travel compensation from Desitin. IC was consultant and / or speaker for Danone, Neuraxpharm, Zambon GmbH, Abbvie GmbH, Desitin and Bial GmbH, and she received travel compensation from Abbvie. WJ received consultancy fees or speaker honoraria from Abbvie GmbH, Bial GmbH, Desitin, Stada and Zambon GmbH. ZK was consultant and / or speaker for Bial GmbH and Stadapharm GmbH, and he received travel compensation from Desitin and Medtronic. SL has no competing interests to declare that are relevant to the content of this article. He has received honoraria vom Abbvie GmbH and travel from Bial GmbH. DP received honoraria as a speaker at symposia sponsored by AbbVie Inc., Bayer, Bial, Boston Scientific Corp., Esteve Pharmaceuticals, Medtronic and Zambon. He received consultancy fees from AbbVie Inc., Bial, Boston Scientific Corp., Bayer, and Desitin, and he was awarded a scientific grant from Boston Scientific Corp. for a project entitled “Sensor-based Optimization of Deep Brain Stimulation Settings in Parkinson’s Disease” (COMPARE-DBS: Computerized Parameter Optimization of Deep Brain Stimulation in Idiopathic Parkinson’s Syndrome). Lastly, DJP had his travel expenses reimbursed by Bial, Desitin, Esteve Pharmaceuticals GmbH, and Boston Scientific Corp. for conference participation. PL reports grants from the Bundesministerium für Bildung und Forschung and the Deutsche Forschungsgemeinschaft; consulting fees from AbbVie, Amylyx, Bial, Desitin, ITF Pharma, Novartis, Stadapharm, Raya Therapeutic, Woolsey Pharmaceuticals, and Zambon; partially unrelated to the scope of the submitted work.
